Monovalent Copper Wound Formulations With In Situ Cu(I) Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial treatments for chronic wounds and implants are not as effective as they could be, with silver ions being less potent than monovalent copper ions, and divalent copper ions being unstable in aqueous environments.
Innovation Solution
A formulation using monovalent copper ions generated in situ by reducing divalent copper ions with ascorbyl palmitate or ascorbic acid, stabilized by acetonitrile, for use in dressings and bandages to prevent wound infections and implant infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If divalent copper ions are used in aqueous environment, then antimicrobial effect is achieved, but stability is poor due to easy oxidation to Cu(II)
Solution Approach 1:
The patent introduces a reducing agent (ascorbic acid or ascorbyl palmitate) as an intermediary substance that continuously converts Cu(II) to Cu(I) in the aqueous wound environment. This mediator maintains the desired Cu(I) state without requiring the formulation itself to be unstable, resolving the contradiction between achieving antimicrobial effect and maintaining stability.
Solution Approach 2:
The patent changes the oxidation state parameter of copper from the stable but less effective Cu(II) to the unstable but more effective Cu(I) by controlling the redox environment through reducing agents. This parameter change enables the formulation to maintain high Cu(I) concentrations in aqueous environment despite the natural tendency to oxidize.
2Reliability
If silver ions are used for wound treatment, then antimicrobial effect is achieved, but efficacy is lower compared to monovalent copper ions
Solution Approach 1:
The patent changes the metallic ion parameter from silver ions to monovalent copper ions, achieving superior antimicrobial efficacy while reducing the risk of resistance development. The Cu(I) ion's unique redox properties and mechanism of action provide enhanced effectiveness against multidrug-resistant pathogens compared to traditional silver ion treatments.
3Stability of the object's composition
If cuprous ions are stabilized with complexing agents like acetonitrile or benzoic acid, then stability is improved, but complexity of formulation increases
Solution Approach 1:
The patent uses ascorbic acid or ascorbyl palmitate as simple, inexpensive reducing agents that are already commonly used in wound care formulations. These short-living reducing agents continuously regenerate Cu(I) from Cu(II) without requiring complex stabilizing structures, maintaining simplicity while achieving stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Monovalent copper ions demonstrate superior antimicrobial efficacy, reducing bacterial and yeast viability by up to 7 logs within hours, and maintaining effectiveness over time, making them more effective than silver and divalent copper ions.
Implementation Method 1
monovalent copper ions (cuprous, Cu +1) in situ by reduction of divalent copper ions (cupric, Cu +2) with ascorbyl palmitate or ascorbic acid
Implementation Method 2
it is possible to maintain high concentration of cuprous ions in aqueous environment by adding reagents which form a very stable complex with the cuprous ion, such as acetonitrile
Implementation Method 3
The mechanisms behind copper toxicity are still a subject of ongoing research, but a number of contributing factors have already been established. A major factor is the ability to act as a catalyst for oxidative damage to tissues through cyclic redox reactions, alternating between Cu(I) and Cu(II). The reactive oxygen species generated in these reactions directly damage essential cell components like nucleic acids, proteins, and lipids.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to antimicrobial formulations. More particularly, the invention relates to monovalent copper-containing and/or monovalent copper-generating products for healing wounds and burns, and particularly for chronic wounds, prevention of wound infections and infections in various implants as well as medical/surgical devices.